logo

BTSG

BrightSpring Health·NASDAQ
--
--(--)
--
--(--)
7.49 / 10
Outperform

BTSG scores 7.5/10 on fundamental health, driven by strong YoY growth in earnings per share (411.11% basic, 388.89% diluted) and net cash flow from operations (472.77% per share). Metrics like Asset-MV (-0.50) and Cash-MV (-0.19) place the stock in higher performance quartiles, though Net Income/Revenue (-1.83) is a concern. Overall, the fundamentals point to a quality company with solid growth, yet some profitability inefficiencies remain.

Fundamental(7.49)SentimentTechnical

Analysis Checks(8/10)

Revenue-MV
Value1.76
Score2/3
Weight6.06%
1M Return2.84%
Net cash flow from operating activities per share (YoY growth rate %)
Value472.77
Score3/3
Weight15.15%
1M Return5.16%
Net income-Revenue
Value-1.83
Score0/3
Weight-0.53%
1M Return-0.21%
Basic earnings per share (YoY growth rate %)
Value411.11
Score3/3
Weight13.42%
1M Return4.75%
Total profit (YoY growth rate %)
Value165.31
Score3/3
Weight17.45%
1M Return6.14%
Net cash flow from operating activities (YoY growth rate %)
Value486.92
Score3/3
Weight15.50%
1M Return5.21%
Diluted earnings per share (YoY growth rate %)
Value388.89
Score3/3
Weight14.51%
1M Return5.10%
Asset-MV
Value-0.50
Score2/3
Weight7.69%
1M Return3.30%
Net profit attributable to parent company shareholders (YoY growth rate %)
Value433.48
Score3/3
Weight11.50%
1M Return4.09%
Cash-MV
Value-0.19
Score0/3
Weight-0.74%
1M Return-0.31%
Is BTSG undervalued or overvalued?
  • BTSG scores 7.49/10 on fundamentals and holds a Discounted valuation at present. Backed by its 6.54% ROE, 0.96% net margin, 55.23 P/E ratio, 3.93 P/B ratio, and 382.61% earnings growth, these metrics solidify its Outperform investment rating.